Schrodinger reported robust software and drug discovery revenue in the second quarter. Lilly's planned multi-billion-dollar acquisition of Morphic also provides another validation point for ...

Schrödinger, Inc. (Nasdaq: SDGR) will report its fourth quarter and full-year 2025 financial results on Wednesday, February 25, 2026, after the financial markets close. The company will host a ...

Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant Novartis that could generate $2.3 billion in milestone and royalty payments ...

Schrodinger reported strong Q4 2023 results, but weak guidance for 2024, causing a significant drop in the share price. The demand environment continues to impact the software business, with growth ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) provided an update on its progress across the business in 2025 and announced its strategic priorities for 2026. The company is continuing to ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), today announced that it is broadening and accelerating its initiative to expand the company’s computational platform to predict toxicology ...

During the last three months, 4 analysts shared their evaluations of Schrodinger (NASDAQ:SDGR), revealing diverse outlooks from bullish to bearish. The following table encapsulates their recent ...

Schrodinger, Inc. SDGR shares ended the last trading session 14.1% higher at $24.34. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

A downtrend has been apparent in Schrodinger, Inc. (SDGR) lately. While the stock has lost 15.5% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last ...

Schrödinger has two segments: drug discovery and software revenue. The company, after the markets closed on Wednesday, reported second-quarter revenue of $35.2 million, down 9% year over year, and net ...

Bank of New York Mellon Corp cut its stake in Schrödinger, Inc. (NASDAQ:SDGR – Free Report) by 6.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange ...